FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • FAQ
  • How to use FRC

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Nika Pharmaceuticals Inc. Stock AnalysisComprehensive stock analysis for Nika Pharmaceuticals Inc. (NIKA) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisNIKA
NIKA
Nika Pharmaceuticals Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
NIKA
Home🔹Stocks🔹Nika Pharmaceuticals Inc.

Nika Pharmaceuticals Inc.

🇺🇸NIKA•OTC

Nika Pharmaceuticals Inc.

🇺🇸NIKA•OTC
Market cap
$785.60M
Sentiment

Your view on NIKA

Mkt Cap
$785.60M
Sentiment
Your view
NIKA
Nika Pharmaceuticals Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
NIKA
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Nika Pharmaceuticals Inc.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Dimitar Slavchev Savov
Headquarters
2269 Merrimack Valley Avenue, Henderson, NV, US
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Dimitar Slavchev Savov
Headquarters
2269 Merrimack Valley Avenue, Henderson, NV, US
Description

Nika Pharmaceuticals, Inc., a pharmaceutical company, develops drugs for the treatment of HIV/AIDS, hepatitis B and C, rheumatoid arthritis, cancer, diabetes, and various other diseases. It offers dietary supplements and antiviral drugs, as well as thymus nuclear glycoprotein for the treatment of HIV.

The company was formerly known as Centennial Growth Equities Inc. and changed its name to Nika Pharmaceuticals, Inc. in May 2022. Nika Pharmaceuticals, Inc. was incorporated in 2000 and is based in Henderson, Nevada.

FRC Research

Media

Infographics, videos, and posts covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks it is worth vs. the current price.

FRC's fair value estimate for Nika Pharmaceuticals Inc., and the rating behind it. NIKA last traded at $0.76; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for Nika Pharmaceuticals Inc.. Starting points for Nika Pharmaceuticals Inc.: beta -0.69 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for Nika Pharmaceuticals Inc.. Nika Pharmaceuticals Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for Nika Pharmaceuticals Inc.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for Nika Pharmaceuticals Inc.. Nika Pharmaceuticals Inc. has reported as a listed company since 2024. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Nika Pharmaceuticals Inc. valued side by side against its closest peers. Nika Pharmaceuticals Inc. is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

Institutional Ownership

Premium

Which funds and firms own the stock.

Which institutions hold Nika Pharmaceuticals Inc., and how their positions are changing. At a $785.6M market value, institutional positions materially move Nika Pharmaceuticals Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Insider Trading

Premium

Recent buying and selling by company executives.

Buying and selling by Nika Pharmaceuticals Inc. executives and directors. Shares of Nika Pharmaceuticals Inc. have traded between $0.25 and $1.00 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

Senate Trading

Premium

U.S. Senator disclosures filed under the STOCK Act.

U.S. Senate disclosures naming Nika Pharmaceuticals Inc.. Nika Pharmaceuticals Inc. is a $785.6M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

House Trading

Premium

U.S. Representative disclosures filed under the STOCK Act.

U.S. House of Representatives disclosures naming Nika Pharmaceuticals Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

News

Latest headlines and market coverage.

Latest headlines and company announcements for Nika Pharmaceuticals Inc.. Coverage tracks Nika Pharmaceuticals Inc. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.

Peer companies

  • ABTI — Alterola Biotech, Inc.
  • BHCCF — Benchmark Holdings plc
  • COGZF — Cogstate Limited
  • CPHRF — Cipher Pharmaceuticals Inc.
  • EDTXF — Spectral Medical Inc.
  • FGHQF — Frontage Holdings Corporation

More Drug Manufacturers - Specialty & Generic companies

  • PSIQ — Profile Solutions, Inc.
  • PTLF — Petlife Pharmaceuticals, Inc.
  • PTPI — Petros Pharmaceuticals, Inc.
  • PWR.CN — Captiva Verde Wellness Corp.
  • PZOO — Pazoo, Inc.
  • RAFA — Rafarma Pharmaceuticals, Inc.
  • RAMM.CN — RAMM Pharma Corp.
  • RAPH — Raphael Pharmaceutical Inc.
  • RDDTF — Radient Technologies Inc.
  • RDHL — RedHill Biopharma Ltd.
  • RDY — Dr. Reddy's Laboratories Limited
  • REZNF — Street Capital Inc.

News

Latest Market News